* required

News & Events

Gulf Coast Eye Institute has Vision for a Healthy Community!

As seen in The Monitor, GCE team members recently performed eye screenings at the Winter Texan Expo and Health Fair.

Click here to see it online!


Cataract Awareness on Good Morning Valley!


Dr. Nehal Patel, board-certified ophthalmologist with Gulf Coast Eye Institute, recently sat down with Mary Avila-Shears on the Daytime at Nine segment of Good Morning Valley. Dr. Patel spoke about cataract awareness and recent advancements in the field.

After more than a decade in practice, Dr. Patel is still fascinated by the eye.

“It’s a phenomenal opportunity to be involved in this field, to provide quality care and to restore vision in individuals who are suffering and not seeing.”

Where cataracts is concerned, Dr. Patel explained it this way: “Everyone is born with a natural lens inside their eye,” he said. “Because of aging, these lenses can turn cloudy. The way we take care of this problem has changed tremendously over the years - from the type of surgery we do to the technology to the way we rehabilitate vision.”

“Things are always changing,” he added. “Surgical techniques change. Technology changes. Most recently, laser assisted cataract surgery has come into play. The femtosecond laser is now something we use in cataract surgery. We don’t to use any blades anymore. It’s all blade free.”

Gulf Coast Eye is one of the only practices in the Valley that’s involved in cataract research. “We have always utilized state of the art technology and every possible advancement that’s available to us,” said Dr. Patel. “We also have very experienced doctors. We specialize in cataract surgery but we also have specialists in glaucoma and retina issues. We always evaluate the whole patient and do our best to restore their vision.”  



Join us Wednesday, August 12, for our Laser Cataract Surgery Seminar!

Laser Cataract Surgery Seminar


Join Us for Our Upcoming Summer Seminar Series Events

LASIK and Cataract Surgery Seminar

Seminars will begin at 5:30 p.m. in their respective locations. The seminars will cover subject material regarding both Blade-Free LASIK and cataract treatment options. Please RSVP to save your seat by calling Becky at 956.421.5277. 

Dr. Gonzalez Featured in ILUVIEN® Live Webinar Launch Event!

We are honored that our very own Victor Gonzalez, MD, is one of the first retinal specialists in the country to administer this potentially groundbreaking treatment for patients suffering from diabetic macular edema.

See excerpts from the official news release below, in which Alimera Sciences, Inc announces their live ILUVIEN webcast.

Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a pharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced it will host a live webinar for eye care professionals on Monday, March 2, 2015, at 8:30 p.m. EST, during which eight leading retinal specialists and one glaucoma specialist from around the country will share their early experiences with ILUVIEN® (fluocinolone acetonide intravitreal implant) 0.19mg. Initial nationwide shipments of ILUVIEN, the first treatment for diabetic macular edema (DME) that provides 36 months of sustained drug delivery in a single intravitreal implant, will begin nationally on February 23, 2015.

The one-­hour launch event, accessible online through a live webcast, will feature ILUVIEN case studies, previously recorded ILUVIEN injections and a live audience Q&A. This webcast is specifically designed for the professional eye care community and will allow physicians to freely exchange information on ILUVIEN with their colleagues in an open forum. Alimera executives will be on hand, as well, to address questions related to product distribution and reimbursement opportunities. Those interested in registering for the webinar are encouraged to do so in advance at

“We are very excited to announce the official U.S. commercial launch of ILUVIEN with the retinal community, many of whom have closely followed the development and approval of the product over the years. We chose this novel webinar launch approach in order to disseminate information about ILUVIEN to them as efficiently and effectively as possible,” said Dan Myers, president and chief executive officer of Alimera. “It is our hope that by providing this open discussion platform, physicians will feel empowered to take advantage of this cutting­edge treatment option and make it quickly available to their appropriate DME patients.”

ILUVIEN was approved by the U.S. Food and Drug Administration (the FDA) in September 2014 to treat DME in patients who have been previously treated with a course of corticosteroids and did not have a clinically significant rise in intraocular pressure (IOP). It is expected that ILUVIEN will be reimbursed per its FDA indication. Alimera has a reimbursement and patient assistance program, AccessPlus, which is available to support practices and patients.

“The proven effectiveness combined with the inherent convenience of a multiyear drug delivery system delivered in a single injection has had DME patients and the retinal community eagerly awaiting ILUVIEN’s commercial availability,” said Nancy Holekamp, M.D., retina specialist at Pepose Vision, Chesterfield, Missouri, and moderator of the webinar event. “DME patients can be challenging, and while treatment options have improved greatly in recent years, they still often require multiple injections and can be burdensome to the patient. ILUVIEN expands our ability to treat these patients with an implant that slowly releases a corticosteroid for 36 months.”

In addition to Dr. Holekamp, other webinar presenters include: Dr. David Brown, Retina Consultants of Houston, Houston, Texas; Dr. Pravin Dugel, Retinal Consultants of Arizona, Phoenix, Arizona; Dr. Alexander Eaton, Retina Health Center, Fort Myers, Florida; Dr. Victor Gonzalez, Valley Retina Institute, McAllen, Texas; Dr. Peter Kaiser, Cole Eye Institute, Cleveland Clinic, Cleveland, Ohio; Dr. Szilàrd Kiss, Weill Cornell Medical College, New York­ Presbyterian Hospital, New York, New York; Dr. Baruch Kuppermann, U.C. Irvine Medical Center, Orange, California; and Dr. Thomas Mundorf, Mundorf Eye Center, Novant Health Presbyterian Medical Center, Charlotte, North Carolina.

“As retina specialists, we continuously strive to help our patients preserve their vision and their quality of life. While the DME treatment option landscape has expanded over the past several years, we do see a significant percentage of patients who don’t respond or eventually fail to respond,” said Dr. Kiss. “ILUVIEN gives us a truly long­lasting and effective treatment to add to our DME arsenal and gives our patients additional hope that their visual acuity can be maintained.”